OCT 22, 2020 4:20 PM CEST

NGS evolution in Solid Tumours, from S5-XL to Genexus

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director of Molecular Biology Laboratory, Department of Pathology - Vall d´Hebron Hospital
    Biography



      Dr. Hernández Losa is Director of Molecular Biology Laboratory in the Department of Pathology from the Vall d´Hebron Hospital in Barcelona. He has trained in Cancer Research, focusing on the signaling and virus detection pathways in FFPE human samples at the Department of Pathology in Hospital Puerta de Hierro (Madrid). After his Ph.D. in Biochemistry and Molecular Biology, he moved to Vall d´Hebron Hospital endorsing extensive experience in drug synergisms in different in vitro models of breast and pancreatic cancer, also in the field of biomarkers, being today one of the reference laboratories in Molecular Pathology. In addition in the last five years, the laboratory has validated by immunohistochemistry more than 12 prognostic and/or predictive markers of cancer. Thanks to these molecular analyzes based on real-time PCR and NGS have contributed to the selection of patients for the different clinical trials carried out at our institution. Dr. Hernández-Losa has been also involved in different technologies validation for mutational analysis of KRAS, NRAS, BRAF, PIK3CA, and EGFR genes in samples from colorectal cancer and NSCLC patients, as well as in exosome samples obtained from primary tumors.


    Abstract

    During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally, he will explain the key questions to implement Genexus in the Molecular Biology Laboratory. Finally, he will describe the experience of tumor samples analysis by Genexus and the comparative data vs different NGS panels and platforms in NSCLC samples.

    Learning Objectives:
    1. S5 evolution of service and benefits of NGS by Genexus
    2. Set-up of Genexus in a Molecular Laboratory


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    NOV 05, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 05, 2020 7:00 AM PST
    DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    Loading Comments...
    Show Resources